NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Stablepharma

Stablepharma

Private
BathHealthcare & Life Scienceshttps://stablepharma.com/

Last Round

Grant

Feb 19, 2025

Est. Valuation

$50.25M

Total Funding Raised

$12.31M

Company Overview

Stablepharma is a biotechnology company that develops a technology platform to transform approved vaccines, therapeutics, and diagnostics into thermostable products, ensuring safe and efficient delivery while minimizing waste and carbon emissions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

thermostabilizationfridge-free vaccinescold-chain logisticscold chain freevaccine technologyvaccine techbiologics stabilizationroom temperature storagepharmaceutical formulationlyophilizationvaccine accessbiotech licensingdrug deliverylast mile deliveryglobal health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Stablepharma Comparables

Compare Stablepharma with similar companies based on industry and business-model similarity.

Stablepharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VitriVax, Inc.
87%
Inaedis Inc.
84%
EnsiliTech
83%

Stablepharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 19, 2025
CrowdfundingJun 14, 2024
VC RoundOct 23, 2023
GrantSep 12, 2023
Series ADec 23, 2022
Crowdfunding
Aug 5, 2021

Key People

Founding team and executive leadership

Özgür Tuncer

CEO & Executive Director

Executive Team

Kenny Simmen

Chief Business Officer, Advisory Board Member

Executive Team

Stablepharma Investors

Notable investors and investment history

Stablepharma investors
InvestorRounds
Crowdcube InvestorsCrowdfunding, VC Round, Series A, Seed
European Innovation Council FundGrant
Ascension VenturesSeries A
Innovate UKGrant
Oval Investments LimitedSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 13, 2026

    SPVX02 targets tetanus and diphtheria, developed with UKHSA support.

  • Jan 15, 2026

    Developing fridge-free sterile injectable medicines with AFT Pharmaceuticals.

Stablepharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Stablepharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Stablepharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersBath
Employee Range26
Year Founded2012
Last FundingFeb 19, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.